CON	Comeback
REL	Cancers
GPE	LONDON
EQU	,
GPE	ONTARIO
NIL	–
ORG	Progress
NOW	is
EXS	being
EXS	made
AND	against
QUV	many
CON	types
AND	of
CON	cancer
NIL	,
REL	with
IST	more
CON	patients
EXG	surviving
IST	longer
NIL	,
CON	thanks
REL	to
CON	research
REL	on
QUC	two
CON	fronts
AND	:
IST	improved
CON	methods
REL	for
MOR	earlier
CON	detection
NIL	,
AND	and
CON	development
AND	of
CON	therapies
AND	that
NOW	are
IST	more
EXS	effective
AND	and
LES	less
IST	toxic
NIL	.
AND	Indeed
NIL	,
PRO	it
NOW	is
EXS	estimated
SUB	that
UNK	there
NOW	are
NOW	now
MOR	more
MOR	than
QUC	10 million
CON	cancer
CON	survivors
REL	in
DEF	the
CON	United States
AND	alone
NIL	,
AND	and
PRX	this
CON	number
NOW	has
PFT	been
IST	steadily
EXS	increasing
NIL	.
IST	Similar
CON	numbers
NIL	,
REL	in
CON	proportion
REL	to
CON	population
CON	sizes
NIL	,
NOW	are
EXS	found
REL	in
ALT	other
IST	developed
CON	countries
NIL	.
CON	Cancers
AND	that
NOW	are
EXS	detected
IST	early
NIL	–
SUB	when
PRO	they
NOW	are
IST	small
AND	and
IST	less
IST	likely
SUB	to
EXT	have
EXS	metastasized
SUB	(
EXS	spread
IST	away
REL	from
DEF	the
IST	primary
CON	tumor
NIL	)
AND	–
NOW	are
IST	more
IST	likely
SUB	to
EXS	be
IST	treatable
REL	with
IST	local
CON	therapy
NIL	,
AND	whereas
IST	successful
CON	treatment
NOW	is
IST	ultimately
UNK	unlikely
SUB	once
EXS	metastatic
CON	tumors
EXS	develop
NIL	.
AND	And
IST	improved
CON	therapies
NOW	mean
SUB	that
CON	patients
POS	can
EXS	be
EXS	treated
REL	with
CON	drugs
SUB	that
EXS	work
COM	better
NIL	(
COO	and
SUB	that
CON	patients
NOW	are
IST	more
UNK	likely
SUB	to
EXS	receive
DEF	the
IST	full
CON	dose
EPS	needed
NIL	)
NIL	.
AND	But
HAS	our
IST	dramatic
CON	progress
REL	in
EXS	detecting
COO	and
EXS	treating
CON	cancer
NOW	has
IST	also
EXS	led
REL	to
EXG	growing
CON	awareness
AND	of
DEF	the
CON	problem
AND	of
CON	tumor
CON	dormancy
AND	:
DIS	a
CON	patient
ENS	appears
SUB	to
EXS	be
EXS	cured
NIL	,
XCL	only
SUB	to
EXS	have
DEF	the
IST	same
CON	cancer
CON	return
CON	years
DIS	or
IST	even
CON	decades
AND	later
NIL	.
REL	In
CON	breast
CON	cancer
DIS	or
CON	melanoma
NIL	,
REL	for
CON	example
EQU	,
CON	recurrences
QUC	25
CON	years
REL	after
IST	initial
CON	treatment
NOW	have
PFT	been
EXS	reported
NIL	.
REL	With
DIS	a
EXG	growing
CON	number
AND	of
CON	cancer
CON	survivors
NIL	,
PRO	we
ENS	need
SUB	to
EXS	understand
IST	better
DEF	the
IST	twin
CON	processes
AND	of
CON	tumor
CON	dormancy
AND	and
IST	metastatic
CON	cancer
CON	recurrence
NIL	.
SUB	While
IST	remarkable
CON	progress
NOW	has
PFT	been
EXS	made
REL	in
CON	understanding
DEF	the
CON	biology
AND	of
CON	cancer
AND	–
EXG	leading
REL	in
CON	part
REL	to
DEF	the
CON	development
AND	of
IST	new
NIL	,
LES	less
IST	toxic
CON	drugs
AND	–
HAS	our
CON	understanding
AND	of
DEF	the
CON	biology
AND	of
CON	tumor
CON	metastasis
NIL	,
COO	and
AND	especially
DEF	the
CON	development
AND	of
CON	metastases
REL	after
DIS	a
IST	long
CON	period
AND	of
CON	tumor
CON	dormancy
NIL	,
NOW	has
IST	lagged
NIL	.
PRO	We
NOW	do
EXS	know
SUB	that
CON	metastasis
NOW	is
DIS	a
INT	very
IST	inefficient
CON	process
NIL	,
REL	with
TOP	most
CON	cancer
CON	cells
SUB	that
EXS	escape
REL	into
DEF	the
CON	blood
CON	stream
EXS	failing
SUB	to
EXS	form
IST	metastatic
CON	tumors
REL	in
IST	distant
CON	organs
NIL	.
IST	Recent
CON	studies
NIL	–
REL	from
AND	both
DEF	the
CON	laboratory
AND	and
DEF	the
CON	clinic
NOW	–
EXS	suggest
SUB	that
QUV	many
CON	cancer
CON	cells
SUB	that
EXS	leave
DEF	the
IST	primary
CON	tumor
POS	may
CON	lodge
REF	themselves
REL	in
IST	new
CON	organs
COO	and
EXS	go
REL	into
DIS	a
EXS	dormant
CON	state
NIL	.
PRO	We
ALT	also
NOW	have
CON	evidence
AND	that
ENS	says
SUB	that
PRX	these
EXS	dormant
CON	cells
POS	may
EXS	resist
INT	most
IST	current
CON	treatments
NIL	.
PRX	This
NOW	means
SUB	that
IST	adjuvant
CON	cancer
CON	therapy
NIL	,
EXS	designed
SUB	to
EXS	kill
EXS	presumed
IST	micrometastatic
CON	disease
NIL	,
POS	may
EXS	be
EXS	missing
DIS	an
IST	important
CON	fraction
AND	of
IST	disseminated
CON	cancer
CON	cells
NIL	,
DIS	some
AND	of
UNK	which
POS	may
IST	eventually
EXS	wake
IST	up
NIL	.
AND	Moreover
NIL	,
PRO	we
NOW	are
EXS	beginning
SUB	to
EXS	identify
IST	molecular
CON	mechanisms
SUB	that
EXS	regulate
DEF	the
CON	entry
AND	of
CON	cancer
CON	cells
REL	into
DIS	a
EXS	dormant
CON	state
NIL	,
AND	as
IST	well
AND	as
HAS	their
CON	re-awakening
REL	at
IST	later
CON	times
NIL	.
HAS	Our
CON	knowledge
AND	of
DEF	the
CON	regulation
AND	of
CON	tumor
CON	dormancy
NOW	is
IST	really
REL	in
HAS	its
CON	infancy
NIL	.
